Cobra Biologics, Novolytics Achieve Bacterial Breakthrough

Cobra Biologics Ltd. and Novolytics have achieved a milestone in the development of two Staphylococcus aureus based phage products for Phase I trials with a 100 fold increase in upstream process yields. An existing process was transferred to Cobra’s phage team for further process development in order to increase yields for the two Staphylococcus aureus based phage products. The controlled, high yield process provides Novolytics with a path forward to producing suitable GMP material for human clinical trials.
   
Peter Coleman chief executive officer of Cobra Biologics, said, “It is very exciting to be engaged with such novel phage products and to be actively assisting pioneering companies like Novolytics to introduce ground breaking anti-infectives. The phage team has considerable experience in developing processes for such novel products and looks forward to working closely with Novolytics.”
 
John Hardcastle, chief executive officer of Novolytics, said, “Cobra is helping Novolytics to produce bacteriophage cocktails that remain therapeutically active when produced to GMP standard and on an industrial scale. This is a critical factor for successful exploitation of the exciting potential that phage therapy offers.”